HER2 therapy: Molecular mechanisms of trastuzumab resistance
-
Corresponding authors: Rita Nahta rnahta@mdanderson.org - Francisco J Esteva festeva@mdanderson.org
Breast Cancer Research 2006, 8:215 doi:10.1186/bcr1612
Accesses
- Last 30 days: 290 accesses
- Last year: 2830 accesses
- All time: 16088 accesses
Cited by
BioMed Central: 8 citations
|
Research
Phillip Kim, Xinjun Liu, Tani Lee, Limin Liu, Robert Barham, Richard Kirkland, Glen Leesman, Anne Kuller, Belen Ybarrondo, Shi-Chung Ng, Sharat Singh Proteome Science 2011, 9:75 (15 December 2011) |
|
Proceedings
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone Edgardo Rivera, Henry Gomez Breast Cancer Research 2010, 12(Suppl 2):S2 (22 October 2010) |
|
Research article
Andrea Sassen, Simone Diermeier-Daucher, Manuela Sieben, Olaf Ortmann, Ferdinand Hofstaedter, Stephan Schwarz, Gero Brockhoff Breast Cancer Research 2009, 11:R50 (22 July 2009) |
|
Technical advance
Hannah Jörißen, Nuran Bektas, Edgar Dahl, Arndt Hartmann, Anette ten Haaf, Stefano Di Fiore, Hans Kiefer, Andreas Thess, Stefan Barth, Torsten Klockenbring BMC Cancer 2009, 9:200 (24 June 2009) |
|
Research
A sequence-based survey of the complex structural organization of tumor genomes Benjamin J Raphael, Stanislav Volik, Peng Yu, Chunxiao Wu, Guiqing Huang, Elena V Linardopoulou, Barbara J Trask, Frederic Waldman, Joseph Costello, Kenneth J Pienta, Gordon B Mills, Krystyna Bajsarowicz, Yasuko Kobayashi, Shivaranjani Sridharan, Pamela L Paris, Quanzhou Tao, Sarah J Aerni, Raymond P Brown, Ali Bashir, Joe W Gray, Jan-Fang Cheng, Pieter de Jong, Mikhail Nefedov, Thomas Ried, Hesed M Padilla-Nash, Colin C Collins Genome Biology 2008, 9:R59 (25 March 2008) Tumors and cancer cell lines were surveyed with end-sequencing profiling, yielding the largest available collection of sequence-ready tumor genome breakpoints and providing evidence that some rearrangements may be recurrent. |
|
Research article
Nuran Bektas, Anette Haaf, Jürgen Veeck, Peter Wild, Juliane Lüscher-Firzlaff, Arndt Hartmann, Ruth Knüchel, Edgar Dahl BMC Cancer 2008, 8:42 (6 February 2008) |
|
Research article
Yanyuan Wu, Hezla Mohamed, Ram Chillar, Ishrat Ali, Sheila Clayton, Dennis Slamon, Jaydutt V Vadgama Breast Cancer Research 2008, 10:R3 (10 January 2008) Activated Akt (pAkt) overexpression in tumours predicts a lower survival rate in African American and Latina women, suggesting pAkt is a potential therapeutic target for these high risk populations.
|
|
Research article
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients Andrea Sassen, Justine Rochon, Peter Wild, Arndt Hartmann, Ferdinand Hofstaedter, Stephan Schwarz, Gero Brockhoff Breast Cancer Research 2008, 10:R2 (8 January 2008) |